Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Company Gifts Linked to Doctors’ Prescribing Habits

Andrew M. Seaman  |  May 15, 2016

(Reuters Health)—Doctors who receive payments or gifts from pharmaceutical companies are more likely to prescribe brand name medications, a new study suggests.

Dr. James Yeh, of Brigham and Women’s Hospital in Boston, and colleagues write May 9 online in JAMA Internal Medicine that some states require doctors to report what they receive from drug companies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the new study, the researchers analyzed 2011 data from Massachusetts payment reports and the prescription drug program of Medicare, the U.S. public health insurance program for the elderly and disabled.

Of the 2,444 Massachusetts doctors in Medicare’s prescribing database, about 37% received payments from the drug industry.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

About 71% of doctors reported receiving meals paid for by drug companies, about 51% reported receiving grants, about 27% received other services and about 11% reported receiving educational training.

Average payments to doctors ranged from $100 to $1,188, the researchers report.

Then the researchers looked at whether those payments were tied to doctors’ prescribing patterns. Specifically, they wanted to know whether doctors who received more gifts prescribed more brand-name cholesterol lowering drugs—known as statins—rather than less expensive generic medications.

Overall, an average of 17.8% of statin prescriptions were for brand name drugs. Every $1,000 of additional funds doctors received was tied to a 0.1% increase in the rate of brand name prescribing.

Although a 0.1% increase may not seem like a lot, the researchers note that the financial effects for patients and the healthcare system can be substantial because brand name statins cost between two and four times more than generic medications.

There was no connection between brand name prescribing and industry payments when doctors received less than $2,000.

“Not surprisingly, the payments that were categorized as educational trainings seemed to most impact brand name prescribing,” says Yeh.

The researchers say their findings are limited by the fact that doctors who prescribe a high number of brand name medications may be sought out by drug companies to promote those products. Also, the findings are based on self-reporting by doctors.

Share: 

Filed under:Drug UpdatesProfessional Topics Tagged with:generic drugsphysicianprescribePrescription drugsStatin

Related Articles

    Ethics Forum: Teach Rheumatology Fellows to Use Good Judgment in Pharmaceutical Company Interactions

    April 19, 2017

    We teach medical students, residents and fellows evidence-based medicine to lay the groundwork for rational prescribing and good clinical judgment. But should we stop our rheumatology fellows from interacting with pharmaceutical companies as part of this foundation? It is not surprising that pharma­ceutical companies can influence physician pre­scribing through gifts. At least, it should not…

    No Easy Solution for Lack of Transparency in the Practice of Medicine

    December 1, 2012

    Several well-publicized episodes highlight the apparent lack of disclosure of conflicts of interest in medicine, but will disclosure laws fix the problem or add to the confusion?

    Ethics Forum: The Ethics of Accepting Gifts

    December 12, 2011

    The holiday season is here and I certainly enjoy receiving gifts as much as anyone. We have been either educated about declining—or forbidden to receive—gifts from pharmaceutical companies, but these are not the only source of gifts. A few years ago, I discovered a private physical therapist was located only a few blocks from my office.

    An Overview of Pediatric, Noninfectious Uveitis

    October 18, 2018

    Uveitis is an inflammation of the uvea, which comprises the iris, ciliary body and choroid. Uveitis can lead to ocular damage and complete visual loss. Noninfectious etiologies for uveitis are the most common in the U.S.1 The estimated incidence of uveitis ranges from 25–52 per 100,000 in adults and five per 100,000 in children. The…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences